This book marks one of the achievements of the Estrogen and Antiestrogen Action: Basic and Clinical Aspects Wisconsin Clinical Cancer Center conference in June 1984. It is not intended to be a recount of the meeting proceedings but is, rather, a historical review of the development of this field of endeavor during the past 30 years. The chapters have been written by many of the leading experts in the field who were asked to recount the development of a particular area or laboratory idea in which they had been personally involved. The book is intended to provide both scientists and clinicians...

In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying targeted hormonal treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen,...

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. This monograph, written by V. Craig Jordan, the "Father of tamoxifen," and his team at Georgetown University illustrates the journey of this milestone in medicine.

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast...